|
Video: What is a Stock Split?
|
|
GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE®) fusion protein immune cell engager technology platform. Co.'s TriKE® platform generate proprietary therapeutics designed to harness and improve the cancer killing abilities of a patient's own natural killer cells. Co. is using its TriKE® platform for immuno-oncology products that can treat a range of hematologic malignancies and solid tumors, as well as to develop therapeutics for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus. According to our GTBP split history records, GT Biopharma has had 2 splits. | |
|
GT Biopharma (GTBP) has 2 splits in our GTBP split history database. The first split for GTBP took place on February 11, 2021. This was a 1 for 17 reverse split, meaning for each 17 shares of GTBP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 58.8235294117647 share position following the split. GTBP's second split took place on February 05, 2024. This was a 1 for 30 reverse split, meaning for each 30 shares of GTBP owned pre-split, the shareholder now owned 1 share. For example, a 58.8235294117647 share position pre-split, became a 1.96078431372549 share position following the split.
When a company such as GT Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the GTBP split history from start to finish, an original position size of 1000 shares would have turned into 1.96078431372549 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into GT Biopharma shares, starting with a $10,000 purchase of GTBP, presented on a split-history-adjusted basis factoring in the complete GTBP split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/28/2018 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$867.00 |
|
End price/share: |
$3.34 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.61% |
|
Average Annual Total Return: |
-59.88% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$38.59 |
|
Years: |
6.08 |
|
|
|
Date |
Ratio |
02/11/2021 | 1 for 17 | 02/05/2024 | 1 for 30 |
|
|